Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This intervention combines the Lactational Amenorrhea Method (LAM) with the advance provision of levonorgestrel emergency contraceptive pills (LNG-ECPs). LAM is a natural family planning method based on the physiological infertility caused by breastfeeding, which is effective only when specific prerequisites are met: the mother is less than six months postpartum, remains amenorrheic, and practices exclusive or near-exclusive breastfeeding. The intervention involves counseling postpartum women on LAM and providing them with a backup supply of levonorgestrel (typically 1.5 mg, either as a single dose or two 0.75 mg doses) to be used if LAM prerequisites expire or are compromised before a long-term contraceptive method is initiated. Levonorgestrel is a synthetic progestogen that prevents pregnancy primarily by delaying or inhibiting ovulation. This specific strategy was evaluated in a randomized trial at Assiut University to increase the uptake of regular contraception and reduce unintended pregnancies in breastfeeding women.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on levonorgestrel + lactational amenorrhea method.